Navigation Links
Drug shows promise for effectively treating metabolic syndrome
Date:7/3/2014

(SALT LAKE CITY)University of Utah researchers have discovered that an enzyme involved in intracellular signaling plays a crucial role in developing metabolic syndrome, a finding that has a U of U spinoff company developing a drug to potentially treat the condition.

The researchers, led by Jared Rutter, Ph.D., professor of biochemistry, hope to begin human clinical trials of a drug in the next couple of years.

"The approved drug therapies do not treat or prevent this condition in most people," says Rutter, senior author of a study describing the research published July 3, 2014, in Cell Reports. "But given the results of our research with mouse and rat models, we are hopeful that metabolic syndrome can be effectively treated with drug therapy someday soon."

Metabolic syndrome, a group of conditions that increases the risk for developing heart disease, diabetes and stroke, is estimated to affect up to 25 percent of adults. Public health officials believe metabolic syndrome has reached epidemic proportions in the United States and elsewhere.

Metabolic syndrome includes disorders such as high blood pressure, high blood sugar levels, abnormal cholesterol readings, and obesity. One of the prominent features of the syndrome is the excessive production and storage of fatty acids and triglycerides.

In research with rodents, Rutter, doctoral student and first author on the Cell Reports study Xiaoying Wu, and Allen Nickols of BioEnergenix, a company Rutter co-founded in 2009, discovered that an enzyme known as PASK stimulates the overproduction of fatty acids and triglycerides. PASK works by chemically modifying other proteins in order to alter their specific functions. One of the proteins it modifies is SREBP-1c, which functions as the master regulator of all of the enzymes that make fat.

Using a drug candidate being developed by the University of Utah spinoff company BioEnergenix, the researchers prevented PASK from modifying SREBP-1c. This, in turn, prevented SREBP-1c from increasing the production of enzymes that make fat, resulting in a drop in the levels of fatty acids and triglycerides in mouse and rat livers. Insulin resistance and diabetes were also partially reversed in diabetes-prone animals.

"We hope that this is an example where science leads us not only to a better understanding of how the body works, but also to the discovery of approaches that we can use to treat human disease," Rutter says.

Researchers don't know what causes fatty acids and triglycerides to be overproduced, and that will be a focus of Rutter's ongoing research as well as trying to understand how PASK activates SREBP-1c.

This study is a prime example of a public/private partnership to advance research and health care, a model becoming more common in medical and other scientific research. In this case, a U of U spinoff company is using a University of Utah-developed technology to improve the knowledge and clinical treatment of an issue with a major impact on U.S. health. To address this health issue, the University of Utah recently established the Center for Diabetes and Metabolism, which pairs researchers and clinicians who work side by side to develop treatment and prevention options. Rutter serves as co-director of this center.


'/>"/>

Contact: Phil Sahm
phil.sahm@hsc.utah.edu
801-581-2517
University of Utah Health Sciences
Source:Eurekalert

Related medicine news :

1. Fear, not data, motivates sunscreen users, research shows
2. New research study shows huge savings for health care
3. Penn study shows changing roles of physicians with MBAs
4. New research shows link unlikely between insomnia symptoms and high blood pressure
5. Study shows cost-effectiveness of smoking cessation counseling during hospitalization
6. Gut bacteria predict survival after stem cell transplant, study shows
7. New post-hoc analysis shows patients with type 2 diabetes undergoing intensification of insulin therapy experienced less nighttime hypoglycemia while being treated with Januvia (Sitagliptin) compared to placebo
8. Moffitt study shows utilizing genetic health care professional reduces unnecessary testing
9. Miriam Hospital study shows how to make statewide health campaigns more effective
10. MRI shows brain abnormalities in late preterm infants
11. Presurgical SPECT/CT shows more cancer than current standard
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
Breaking Medicine Technology: